Congress moves to unmask hidden PBM fees buried in your health plan

What it does

This bill amends federal pension law (ERISA) to classify pharmacy benefit managers (PBMs) as fiduciaries—meaning they must act in the best interest of health plans and workers, not just themselves. It requires PBMs to disclose all compensation they receive (including hidden rebates and fees), prohibits them from indemnifying themselves against liability for breaches, and prevents them from being the primary decision-maker for their own compensation disclosures. The intent is to increase transparency and accountability in how PBMs negotiate drug prices and manage prescription benefits.

Why we flagged it

The bill's core mechanism is straightforward: it reclassifies PBMs as fiduciaries under ERISA and mandates compensation transparency. This is a regulatory accountability measure, not a tax provision, subsidy, or commemorative act. The title accurately describes the functional intent.

What the text implies

• PBMs may respond by restructuring compensation arrangements to appear compliant while maintaining economic benefit through affiliate arrangements or subcontractor pass-throughs, since the bill requires disclosure but does not cap compensation levels.
• The 12-month implementation window may allow PBMs to accelerate rebate collection or restructure contracts before fiduciary duties take effect, potentially front-loading costs to plans.
• Smaller PBMs and third-party administrators may face higher compliance costs than large national PBMs, potentially consolidating the market further.
• The carve-out allowing PBMs to be fiduciaries for their own employee plans creates an asymmetry: PBMs can self-deal on their own plans while being prohibited from doing so on client plans.

Who it affects

Workers and retirees benefit from stronger fiduciary duties on PBMs, mandatory compensation disclosure, and removal of liability shields—all of which should reduce hidden conflicts of interest and lower drug costs. The primary beneficiaries are ordinary people enrolled in employer health plans who currently have no visibility into PBM rebates and fees that inflate premiums.

Who stands to gain

• health plan sponsors (employers)
• workers and retirees (through lower premiums and drug costs)
• transparency-focused healthcare consultants

Named in the bill

pharmacy benefit managers (PBMs), Employee Retirement Income Security Act (ERISA), health insurance issuers, drug manufacturers, drug distributors, group purchasing organizations, rebate aggregators, third-party administrators, ARE (Amedisys, Inc. — mapped stock)

Where it stands

2 cosponsors: 1 Democrats, 1 Republicans.

• Dec 18, 2025 — Introduced · Congress.gov: “Introduced in House”
• Dec 18, 2025 — Referred to House Committee on Education and Workforce · Congress.gov: “Referred to the House Committee on Education and Workforce”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

8 lobbying clients named this bill on 8 disclosure filings across 1 quarter, Jun 2026 to Jun 2026. Those filings disclosed $5,435,526 in lobbying spend. A filing names 18 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 88% of bills with at least one filing.

Jake Auchincloss, the sponsor, reported $785,750 in PAC receipts in the 2026 cycle. $3,000 of that came from 1 PAC tied to these lobbying clients.

• Pharmaceutical Care Management Association — $3,282,990 on 1 filing
• Biogen — $1,060,000 on 1 filing
• Blue Cross Blue Shield of Michigan — $276,347 on 1 filing
• Cystic Fibrosis Foundation — $270,000 on 1 filing
• National Community Pharmacists Association — $270,000 on 1 filing

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.